美股詳情

本頁面由Tiger Trade Technology Pte. Ltd.提供服務

2倍做多NVO ETF-Defiance

18.00

-0.5900-3.17%

盤後：17.97-0.0300-0.17%19:54 EST

成交量：27.73萬

成交額：500.43萬

市值：5,036.58萬

市盈率：- -

高：18.21

開：18.21

低：17.82

收：18.59

52周最高：105.60

52周最低：14.59

股本：279.81萬

流通股本：279.81萬

量比：0.93

換手率：9.91%

股息：- -

股息率：- -

淨資產收益率：--

總資產收益率：--

市淨率：--

市盈率(LYR):- -

資料載入中...

總覽公司新聞資訊公告

2026，全球暢銷藥Top10(預測版)

超級大洗牌！跨國藥企中國市場最新排名

速遞｜擴建海外供應鏈，諾和諾德要把愛爾蘭打造成口服司美格魯肽供應中心

GLP1减重宝典

諾和諾德明星減肥口服藥上市第五周，處方量超3.8萬份

諾和諾德(NVO)盤前升逾1% 擬擴建愛爾蘭工廠欲藉口服版Wegovy搶佔市場份額

GLP‑1戰場轉至口服藥：諾和諾德和禮來同時披露新的全球投資計劃

禮來替爾泊肽國內第5項適應症落地，減肥藥全球版圖已成型，持續擴張中！

摩熵医药大数据

諾和諾德起訴Hims 監管機構關注複方GLP1藥物

环球市场播报

劍指全球市場！諾和諾德(NVO.US)擴建愛爾蘭工廠欲藉口服版Wegovy搶佔市場份額

貝倫貝格：將諾和諾德目標價下調至360丹麥克朗

2026年，這22款藥物值得關注

德銀：諾和諾德仍有機會重新把握肥胖症市場的機遇

环球市场播报

2026開年大戲：這11個III期臨牀數據，誰會引爆？誰會啞火？

BiG生物创新社

德銀：將諾和諾德目標價下調至400丹麥克朗

減肥藥戰局生變：「雙寡頭」分出高下，全球價格血戰中的國產謀突圍丨行業風向標

巔峯之戰！2026藥王爭霸：禮來封神，艾伯維、賽諾菲血拼，強生跌下神壇

諾和諾德減重藥廣告被指誤導消費者，FDA發出警告

藥王易主、山寨藥攪局、專利懸崖倒計時、被指虛假宣傳，諾和諾德全球防線告急

华夏时报网

藥王易主！馬斯克帶貨的減肥「神藥」賣不動了？

Ofweek光电信息网

諾和諾德：GLP-1/GIP/GCG啓動減重二期臨牀

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/stock/NVOX/news"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"NVOX","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"NVOX\",,,,,undefined,":{"symbol":"NVOX","market":"US","secType":"STK","nameCN":"2倍做多NVO ETF-Defiance","latestPrice":18,"timestamp":1771534800000,"preClose":18.59,"halted":0,"volume":277315,"hourTrading":{"tag":"盘后","latestPrice":17.97,"preClose":18,"latestTime":"19:54 EST","volume":7675,"amount":137949.7339,"timestamp":1771548845070,"change":-0.03,"changeRate":-0.001667,"amplitude":0.002778},"delay":0,"changeRate":-0.031737493275954806,"floatShares":2798101,"shares":2798101,"eps":0,"marketStatus":"未開盤","change":-0.59,"latestTime":"02-19 16:00:00 EST","open":18.21,"high":18.21,"low":17.815,"amount":5004270.916285,"amplitude":0.021248,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":2,"ttmEps":0,"tradingStatus":0,"nextMarketStatus":{"tag":"盤前交易","tradingStatus":1,"beginTime":1771578000000},"marketStatusCode":0,"adr":0,"exchange":"ARCA","adjPreClose":18.59,"sharesOutstanding":2738101,"nav":18.61,"aum":50956059.61,"bidAskSpread":0,"preHourTrading":{"tag":"盘前","latestPrice":18.18,"preClose":18.59,"latestTime":"09:29 EST","volume":12225,"amount":225876.39832500002,"timestamp":1771511397962,"change":-0.41,"changeRate":-0.022055,"amplitude":0.012372},"postHourTrading":{"tag":"盘后","latestPrice":17.97,"preClose":18,"latestTime":"19:54 EST","volume":7675,"amount":137949.7339,"timestamp":1771548845070,"change":-0.03,"changeRate":-0.001667,"amplitude":0.002778},"volumeRatio":0.927299,"impliedVol":0.7919,"impliedVolPercentile":0.4819},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"NVOX\",,,,,undefined,":{"symbol":"NVOX","floatShares":2798101,"roa":"--","roe":"--","lyrEps":0,"volumeRatio":0.927299,"shares":2798101,"dividePrice":0,"high":18.21,"amplitude":0.021248,"preClose":18.59,"low":17.815,"week52Low":14.5902,"pbRate":"--","week52High":105.6,"institutionHeld":0,"latestPrice":18,"eps":0,"divideRate":0,"volume":277315,"delay":0,"ttmEps":0,"open":18.21,"prevYearClose":21.89,"prevWeekClose":18.9,"prevMonthClose":28.89,"prevQuarterClose":21.89,"fiveDayClose":18.3,"twentyDayClose":28.92,"sixtyDayClose":19.92},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/NVOX\",params:#limit:5,,,undefined,":[{"market":"US","date":"2025-12-09","symbol":"NVOX","defaultRemindTime":1765290600000,"type":"split","dateTimestamp":1765256400000,"forFactor":8,"toFactor":1,"ratio":8}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"NVOX\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"NVOX\",market:\"US\",delay:false,,,undefined,":{},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"NVOX\",pageSize:20,pageCount:1,lang_content:\"cn\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2612236099","title":"2026，全球暢銷藥Top10(預測版)","url":"https://stock-news.laohu8.com/highlight/detail?id=2612236099","media":"赛柏蓝","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2612236099?lang=zh_tw&edition=fundamental","pubTime":"2026-02-19 17:02","pubTimestamp":1771491774,"startTime":"0","endTime":"0","summary":"在简讯中，Evaluate Pharma分析师对2026年全球十大畅销药品的销售额、排名变动做出专业预测，揭开了未来医药市场的竞争走向。与上一年的预测相比，2026年全球TOP10畅销药品的产品阵容保持不变，但整体销售额有明显的攀升，预计TOP10产品总销售额将接近两千亿美元关口，同比增长达到18%。Eliquis在2026年预计销售额将达121亿美元，但这个极大可能是Eliquis最后一次入选TOP10畅销药榜单。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260219172854954174a0&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260219172854954174a0&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LU0289739699.SGD","SG9999001176.SGD","LU2125154935.USD","LU0861579265.USD","LU0106261372.USD","LU0965508806.USD","IE00B1BXHZ80.USD","LU1917777945.USD","LU0965509101.SGD","LU1989772923.USD","LU2361044949.HKD","SG9999002232.USD","SG9999013999.USD","IE00BLSP4239.USD","LU0320765489.SGD","IE00BN8TJ469.HKD","LU1929549753.HKD","LU2023250843.SGD","BK4559","IE00B2B36J28.USD","LU0203347892.USD","SG9999001440.SGD","SG9999014542.SGD","LU1093756168.USD","LU1699723380.USD","LU1069347547.HKD","LU0238689110.USD","NVOH","LU0432979614.USD","IE00BZ1G4Q59.USD","LU0130102774.USD","LU1989772840.SGD","SG9999015358.SGD","LU1585245621.USD","LU1066051811.HKD","LU1934455194.USD","LU1057294990.SGD","LU0006306889.USD","LU0477156953.USD","LU2324357040.USD","LU1116320737.USD","LU1023059063.AUD","MRK","IE00BKVL7J92.USD","LU1061106388.HKD","LU1066051498.USD","IE00BLSP4452.SGD","LU2360032135.SGD","NVO","LU0266013472.USD","LU1941712348.USD","BK4533","LU1162221912.USD","LU1037948541.HKD","LU1291159041.SGD","BK4588","LU0098860793.USD","LU0965509010.AUD","BK4534","LU2023250504.SGD","LU0265550946.USD","LU0130517989.USD","LU1116320901.HKD","LLY","LU2361045086.USD","SG9999015341.SGD","LU0211331839.USD","LU0203345920.USD","LU1066051225.USD","LU0122379950.USD","IE0009355771.USD","LU0648001328.SGD","SG9999002224.SGD","SG9999001176.USD","NVOX","SGXZ57979304.SGD","BK4599","LU1093756325.SGD","LU1974910355.USD","SG9999014559.SGD","BK4007","LU0965509283.SGD","LU1430594728.SGD","LU0265550359.USD","LU1035773651.USD","IE000M9KFDE8.USD","LU1571399168.USD","SG9999014567.USD","BK4516","SG9999014575.USD","LU1066053197.SGD","IE00BBT3K403.USD","LU2461242641.AUD","LU2089984988.USD","LU0058720904.USD","LU1983299246.USD","BK4532","IE00B4R5TH58.HKD","LU1941712264.USD","LU2106854487.HKD","BK4585","LU0070302665.USD","IE0002141913.USD","LU2125154778.USD","LU2468319806.SGD","LU0234572021.USD","LU1934455863.HKD","IE00BFTCPJ56.SGD","LU0154236417.USD","LU2112291526.USD","LU1201861249.SGD","IE00BJJMRZ35.SGD","LU0320765646.SGD","LU1989771016.USD","IE00BJT1NW94.SGD","LU0980610538.SGD","LU1934455277.USD","LU2361044865.SGD","BK4550","IE00BSNM7G36.USD","LU1037948897.HKD","LU0985320562.USD","LU0208291251.USD"],"gpt_icon":1},{"id":"2611486068","title":"超級大洗牌！跨國藥企中國市場最新排名","url":"https://stock-news.laohu8.com/highlight/detail?id=2611486068","media":"健识局","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2611486068?lang=zh_tw&edition=fundamental","pubTime":"2026-02-16 23:02","pubTimestamp":1771254130,"startTime":"0","endTime":"0","summary":"1月份，跨国药企基本都披露了2025年业绩。礼来则以45%的增幅，营收达651.79亿美元成功反超默沙东，排名第三。而在中国市场，2025年1月，替尔泊肽降糖和减重两项适应症相继上市。2022年至2024年，阿斯利康与默沙东争夺跨国药企中国区营收的“NO.1”，“销售一哥”的宝座每年轮流坐庄。此外，诺华已宣布在中国建立核药生产基地，以支持“派威妥”等放射性药物在中国市场的长期供应。跨国药企把全球创新好药带到中国，才是最好的市场策略。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2026021623082495414b0b&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2026021623082495414b0b&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4007","BK4504","IE00BZ1G4Q59.USD","MCHI","CQQQ","DRAG","LU0154236417.USD","NVOX","BK4588","LLY","LU0963586101.USD","CWEB","LU1093756168.USD","BK4614","LU1093756325.SGD","RHHBY","NVO","AZN","IE00BKVL7J92.USD","NVS","MRK","BK4599","BK4532","NVOH","ASHS","BK4585","ASHR","KWEB"],"gpt_icon":1},{"id":"2611412110","title":"速遞｜擴建海外供應鏈，諾和諾德要把愛爾蘭打造成口服司美格魯肽供應中心","url":"https://stock-news.laohu8.com/highlight/detail?id=2611412110","media":"GLP1减重宝典","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2611412110?lang=zh_tw&edition=fundamental","pubTime":"2026-02-14 22:57","pubTimestamp":1771081043,"startTime":"0","endTime":"0","summary":"至于这次针对口服Wegovy的扩建规模，诺和诺德对外没有给出具体投资额、扩建面积或新增产能的明确数字，但把它定义为非美市场的全球供应中心，本身已经说明其产线与放量节奏会被提升到公司级优先级。诺和诺德之所以要把“非美市场”明确交给爱尔兰，还与它在美国本土的扩产路径同步推进有关。与此同时，诺和诺德在爱尔兰的产能选择也体现出“速度优先”。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2026021423132697a63940&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2026021423132697a63940&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4588","LU0154236417.USD","LU1093756325.SGD","NVOH","BK4585","NVOX","BK4599","NVO","LU1093756168.USD","IE00BZ1G4Q59.USD","IE00BKVL7J92.USD","BK4532","BK4007"],"gpt_icon":1},{"id":"2611152972","title":"諾和諾德明星減肥口服藥上市第五周，處方量超3.8萬份","url":"https://stock-news.laohu8.com/highlight/detail?id=2611152972","media":"财闻","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2611152972?lang=zh_tw&edition=fundamental","pubTime":"2026-02-13 20:50","pubTimestamp":1770987013,"startTime":"0","endTime":"0","summary":"据路透社2月13日消息，IQVIA数据显示，丹麦制药公司诺和诺德（NVO.US）的明星减肥药Wegovy在上市第五周的处方量达到了38,220份。Wegovy是诺和诺德公司开发的一种用于治疗肥胖症的药物。自上市以来，该药物在美国市场的处方量持续增长，显示出其市场需求强劲。随着越来越多的医生和患者了解和认可Wegovy的疗效，预计其处方量还将进一步上升。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260213205119a4a0e331&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260213205119a4a0e331&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4585","NVO","IE00BKVL7J92.USD","BK4588","BK4532","LU1093756168.USD","IE00BZ1G4Q59.USD","LU1093756325.SGD","NVOH","BK4007","NVOX","BK4599","LU0154236417.USD"],"gpt_icon":0},{"id":"2611145151","title":"諾和諾德(NVO)盤前升逾1% 擬擴建愛爾蘭工廠 欲藉口服版Wegovy搶佔市場份額","url":"https://stock-news.laohu8.com/highlight/detail?id=2611145151","media":"金吾财讯","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2611145151?lang=zh_tw&edition=fundamental","pubTime":"2026-02-13 20:06","pubTimestamp":1770984384,"startTime":"0","endTime":"0","summary":"金吾财讯 | 诺和诺德(NVO)盘前涨约1%，截至发稿，报48.960美元。消息面上，诺和诺德计划加大在爱尔兰的投资，在当地生产其畅销减肥药Wegovy的口服版本，以供应美国以外的市场。诺和诺德首席执行官迈克·杜斯达尔表示，诺和诺德将扩建其位于爱尔兰中部阿斯隆(Athlone)的生产设施。","market":"sg","thumbnail":"https://static.szfiu.com/news/20250107/NDkzODU1NDI1NzQyOTYxNg==.png","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20250107/NDkzODU1NDI1NzQyOTYxNg==.png"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"297189","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1093756168.USD","BK4588","NVOX","LU1093756325.SGD","BK4007","BK4532","BK4599","BK4585","IE00BKVL7J92.USD","LU0154236417.USD","NVO","IE00BZ1G4Q59.USD","NVOH"],"gpt_icon":0},{"id":"2611158296","title":"GLP‑1戰場轉至口服藥：諾和諾德和禮來同時披露新的全球投資計劃","url":"https://stock-news.laohu8.com/highlight/detail?id=2611158296","media":"Minhua笔记","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2611158296?lang=zh_tw&edition=fundamental","pubTime":"2026-02-13 16:30","pubTimestamp":1770971414,"startTime":"0","endTime":"0","summary":"尽管诺和诺德在口服减重药的上市节奏上略占先机，但两家公司2月12日均披露了新的投资计划，以加速各自产品的全球推广。根据最新调查，许多患者因害怕注射而更倾向于选择口服药物。这一消息发布前一周，诺和诺德刚公布其减重药业务令人失望的销售指引，预计 2026 年总收入将下降 5%–13%，原因是来自礼来的竞争日益激烈。根据礼来此前的表态，公司预计将拥有足够库存，使该口服减重药能在多个国家几乎同步上市。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260213171818a4a027f1&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260213171818a4a027f1&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["SGXZ99366536.SGD","LU2087625088.SGD","LU2491050154.USD","LU0096364046.USD","LU0640476718.USD","LU2106854487.HKD","LU2896262040.SGD","BK4532","LU1267930730.SGD","LU1974910355.USD","LU2471134796.USD","LU0708995401.HKD","LLYZ","LU0320765992.SGD","SG9999014914.USD","IE00BK4W5L77.USD","LU2211815571.USD","LU2089984988.USD","LU2168564222.USD","LU2417539215.USD","LU2213496289.HKD","SGXZ57979304.SGD","LU1548497426.USD","SG9999014880.SGD","LU2461242641.AUD","LU2236285917.USD","LU0353189763.USD","LU0471298694.HKD","IE00BJJMRZ35.SGD","LU1035775433.USD","BK4534","LU0823434583.USD","LU2456880835.USD","SG9999014906.USD","LU1917777945.USD","LU0683600562.USD","LU0061475181.USD","LU1983299246.USD","LU2552382215.SGD","LU0109394709.USD","LU0158827781.USD","IE00B4R5TH58.HKD","BK4007","LU2746668461.USD","LU0256863811.USD","LU0889565916.HKD","LU0787776722.HKD","LU2023250504.SGD","LU2361044949.HKD","LU0106261372.USD","BK4144","IE00B1BXHZ80.USD","LU0354030438.USD","LU2602419157.SGD","LU1868836914.USD","LU2237443622.USD","LU2168564149.EUR","ELIL","IE00BFSS8Q28.SGD","LU0823434740.USD","LU0786609619.USD","LU2756315664.SGD","BK4585","LU0316494557.USD","NVO","SG9999015986.USD","BK4590","SGXZ81514606.USD","LU1814569148.SGD","LU0256863902.USD","LU1868836591.USD","LU1989771016.USD","LU2552382132.HKD","LU2237443978.SGD","LU2324357040.USD","LU0823416689.USD","LU0109391861.USD","LU2168564495.EUR","LU1023059063.AUD","LU0385154629.USD","SG9999001176.USD","LU0122379950.USD","LU0158827948.USD","LU1291159041.SGD","IE00BFTCPJ56.SGD","LU0198837287.USD","IE00BJJMRX11.SGD","LU0432979614.USD","LU2028103732.USD","LU2168564065.EUR","IE00BWXC8680.SGD","LU0058720904.USD","LU0238689110.USD","LU0882574139.USD","BK4588","LU1145028129.USD","LU1804176565.USD","IE0005OL40V9.USD","LU0094547139.USD","LU0234572021.USD","LU2111349929.HKD","LU2491049909.HKD","LU2756315318.SGD","NVOH","SG9999018865.SGD","IE00B7KXQ091.USD","LU2361044865.SGD","LU1093756168.USD","SG9999013999.USD","LU1551013425.SGD","LU2168563687.JPY","SG9999017495.SGD","LU0964807845.USD","LU1061106388.HKD","LU0154236417.USD","LU2264538146.SGD","LU2750360641.GBP","LU2271345857.HKD","IE00BKPKM429.USD","LU2112291526.USD","BK4599","LU1093756325.SGD","LLYX","BK4516","LU1064131342.USD","IE00BK4W5M84.HKD","LU0203201768.USD","IE0002141913.USD","IE0004445239.USD","LU2746668974.SGD","LU2237443382.USD","SG9999015952.SGD","LU2360106947.USD","LU1720051108.HKD","LU2089283258.USD","IE00BJLML261.HKD","IE00BFSS7M15.SGD","SG9999018857.SGD","LU2265009873.SGD","SG9999014898.SGD","SGXZ51526630.SGD","IE00B2B36J28.USD","IE00BKDWB100.SGD","LU2237438978.USD","IE00BKVL7J92.USD","LU2237443549.SGD","LU2023250330.USD","LU2361045086.USD","IE0009355771.USD","LU1280957306.USD","LU0820561818.USD","IE0004445015.USD","LU1323610961.USD","LU2552382058.USD","LU1127390331.HKD","LU0225283273.USD","LU2471134879.HKD","LU0320765059.SGD","LU1069344957.HKD","ELIS","LU0210536198.USD","LU2750360997.AUD","LU0289739699.SGD","LU2471134952.CNY","LU0417517546.SGD","LU2491050071.SGD","LU2063271972.USD","LU1868837136.USD","LU2108987350.USD","LU0097036916.USD","BK4581","LU2237443465.HKD","LU0266013472.USD","IE00B4JS1V06.HKD","BK4533","LU1868837300.USD","SG9999015945.SGD","LU1988902786.USD","LU0354030511.USD","LU1057294990.SGD","LU2462157665.USD","IE00B775H168.HKD","LU2237443895.HKD","LU2471134523.USD","IE00BJT1NW94.SGD","LU0820561909.HKD","LU0820562030.AUD","IE00BZ1G4Q59.USD","LU1868836757.USD","SG9999001176.SGD","LU1366192091.USD","LU0323591593.USD","GB00BDT5M118.USD","LU1623119135.USD","SG9999015978.USD","LU0079474960.USD","LU1720051017.SGD","LU0882574055.USD","LU2089284900.SGD","IE00BJJMRY28.SGD","LU0353189680.USD","LU1629891620.HKD","LU0456855351.SGD","NVOX","LLY","LU2468319806.SGD","IE00B1XK9C88.USD","LU0471298777.SGD","LU0114720955.EUR","LU0203202063.USD","LU0943347566.SGD","LU1232071149.USD","LU1551013342.USD","LU1712237335.SGD","SGXZ31699556.SGD","LU0672654240.SGD","IE00BN29S564.USD","LU0689472784.USD","LU0006306889.USD","LU2023251221.USD","LU0466842654.USD","LU2357305700.SGD"],"gpt_icon":1},{"id":"2611113808","title":"禮來替爾泊肽國內第5項適應症落地，減肥藥全球版圖已成型，持續擴張中！","url":"https://stock-news.laohu8.com/highlight/detail?id=2611113808","media":"摩熵医药大数据","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2611113808?lang=zh_tw&edition=fundamental","pubTime":"2026-02-13 14:49","pubTimestamp":1770965382,"startTime":"0","endTime":"0","summary":"2月12日，$LLY礼来制药宣布，其GLP-1R/GIPR双重激动剂 替尔泊肽 在国内获批成人2型糖尿病单药治疗新适应症。截图来源：摩熵医药-全球药物研发数据库本次获批后，替尔泊肽 在国内适应症增至5项：T2DM联合治疗：二甲双胍/磺脲类疗效不佳者；T2DM单药治疗：本次新增，饮食运动基础上的成人患者；长期体重管理：BMI≥28（肥胖）或≥24；OSA治疗：成人肥胖患者中重度阻塞性睡眠呼吸暂停；T2DM联合胰岛素：联合胰岛素±口服降糖药控糖。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260213145638a49f9424&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260213145638a49f9424&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["ELIS","IE00B7KXQ091.USD","LU1093756168.USD","LU2357305700.SGD","IE00BJJMRZ35.SGD","LU2471134796.USD","BK4599","IE00BFSS7M15.SGD","LU0820561909.HKD","LU1551013342.USD","LU2456880835.USD","LU0203202063.USD","LU2213496289.HKD","NVOH","LU1868837300.USD","LU1868837136.USD","SG9999018857.SGD","LU0316494557.USD","LU2023250504.SGD","IE00BJLML261.HKD","LU0114720955.EUR","LU2089984988.USD","LU2756315664.SGD","LU0943347566.SGD","LU0823434583.USD","LU2028103732.USD","IE00B1BXHZ80.USD","LU0256863811.USD","LU0456855351.SGD","IE00BWXC8680.SGD","LU0471298777.SGD","LU2237443465.HKD","LU0689472784.USD","LU2750360641.GBP","LU2112291526.USD","LU1232071149.USD","LU2265009873.SGD","LU0353189763.USD","LU2237443978.SGD","LU0320765059.SGD","LU1023059063.AUD","LU0094547139.USD","BK4581","LU0466842654.USD","LU0234572021.USD","IE00BN29S564.USD","LU2168563687.JPY","LU1093756325.SGD","LU0882574139.USD","IE00B4JS1V06.HKD","IE0009355771.USD","LU0708995401.HKD","LU2236285917.USD","LU2491050071.SGD","SG9999014898.SGD","SG9999015945.SGD","LU2168564149.EUR","LU0672654240.SGD","NVOX","LLYZ","LU0820562030.AUD","LU0097036916.USD","LU1323610961.USD","SGXZ31699556.SGD","LU1712237335.SGD","LU2417539215.USD","LU2468319806.SGD","LU1061106388.HKD","SG9999017495.SGD","BK4534","LU1291159041.SGD","LU1974910355.USD","LU2471134952.CNY","LU2361045086.USD","LU2462157665.USD","LU2756315318.SGD","SG9999015952.SGD","IE00B4R5TH58.HKD","LU0109391861.USD","LU2264538146.SGD","BK4007","LU1551013425.SGD","LU0786609619.USD","IE00BJT1NW94.SGD","LU1145028129.USD","LU2063271972.USD","LU2237438978.USD","LU2896262040.SGD","IE00BFTCPJ56.SGD","IE00BKVL7J92.USD","SG9999018865.SGD","IE0002141913.USD","LU1127390331.HKD","GB00BDT5M118.USD","IE00B2B36J28.USD","IE00B775H168.HKD","LU2111349929.HKD","LU2168564065.EUR","LU2237443895.HKD","LU2168564495.EUR","LU2750360997.AUD","IE00BKDWB100.SGD","LU0882574055.USD","LU1629891620.HKD","LU2552382058.USD","LU0640476718.USD","LU0683600562.USD","LU0471298694.HKD","NVO","LU2108987350.USD","LU2023250330.USD","BK4533","LU2089284900.SGD","LU2461242641.AUD","LLY","IE00BZ1G4Q59.USD","LU1623119135.USD","LU2746668461.USD","SG9999014914.USD","LU2471134879.HKD","LU0210536198.USD","LU2271345857.HKD","LU2360106947.USD","LU2168564222.USD","LU0787776722.HKD","IE00BJJMRX11.SGD","LU0320765992.SGD","IE0004445015.USD","LU0823416689.USD","LU1720051108.HKD","LU0198837287.USD","LU1366192091.USD","SG9999015986.USD","LU0122379950.USD","LU2324357040.USD","SG9999001176.USD","LU0266013472.USD","SG9999015978.USD","LU0820561818.USD","LU1868836914.USD","BK4532","LU0964807845.USD","LU0889565916.HKD","LU2361044949.HKD","LU1064131342.USD","LU1069344957.HKD","LU2237443622.USD","SG9999013999.USD","SGXZ99366536.SGD","LU2106854487.HKD","LU2089283258.USD","IE00BK4W5L77.USD","LU2746668974.SGD","LU2491050154.USD","LU0154236417.USD","LU1267930730.SGD","LU0158827781.USD","LU1988902786.USD","LU0061475181.USD","LU0385154629.USD","LU0323591593.USD","LU0823434740.USD","LU2602419157.SGD","SGXZ57979304.SGD","LU1814569148.SGD","LU0106261372.USD","LU2471134523.USD","LU0225283273.USD","LU0058720904.USD","LU1280957306.USD","BK4588","LU0432979614.USD","BK4585","LU2087625088.SGD","LU2237443382.USD","LU2237443549.SGD","IE00BK4W5M84.HKD","LU0203201768.USD","LU2211815571.USD","LU1057294990.SGD","LU1804176565.USD","LU0006306889.USD","LU1868836591.USD","LU1720051017.SGD","SG9999014906.USD","LU0289739699.SGD","LU1989771016.USD","SG9999014880.SGD","SG9999001176.SGD","ELIL","LU1035775433.USD","LU0354030438.USD","LU1548497426.USD","IE00BJJMRY28.SGD","IE0005OL40V9.USD","LU2491049909.HKD","LU1983299246.USD","LU2552382215.SGD","LU2361044865.SGD","LU0109394709.USD","LU0256863902.USD","LU1917777945.USD","SGXZ51526630.SGD","LU0354030511.USD","LU0079474960.USD","BK4516","LU0353189680.USD","LU0238689110.USD","LU2552382132.HKD","IE0004445239.USD","LU2023251221.USD","LLYX","LU1868836757.USD","LU0096364046.USD","SGXZ81514606.USD","IE00BKPKM429.USD","LU0417517546.SGD","LU0158827948.USD","IE00BFSS8Q28.SGD","IE00B1XK9C88.USD"],"gpt_icon":1},{"id":"2610781009","title":"諾和諾德起訴Hims 監管機構關注複方GLP1藥物","url":"https://stock-news.laohu8.com/highlight/detail?id=2610781009","media":"环球市场播报","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2610781009?lang=zh_tw&edition=fundamental","pubTime":"2026-02-12 23:49","pubTimestamp":1770911340,"startTime":"0","endTime":"0","summary":"诺和诺德（NVO）周四早盘上涨1%。该公司提起诉讼，要求阻止Hims & Hers （HIMS） 销售复方司美格鲁肽，数日前美国食品药品监督管理局与卫生及公共服务部暗示将采取执法行动。Hims暂停口服制剂供应，周四早盘该股股价下跌1.5%。\n\n\n海量资讯、精准解读，尽在新浪财经APP\n\n责任编辑：张俊 SF065","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/usstock/c/2026-02-12/doc-inhmqrvx6597100.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["NVOH","BK4007","BK4588","BK4585","BK4599","LU1093756325.SGD","NVO","LU1093756168.USD","BK4532","IE00BKVL7J92.USD","IE00BZ1G4Q59.USD","HIMS","NVOX","LU0154236417.USD"],"gpt_icon":0},{"id":"2610794788","title":"劍指全球市場！諾和諾德(NVO.US)擴建愛爾蘭工廠 欲藉口服版Wegovy搶佔市場份額","url":"https://stock-news.laohu8.com/highlight/detail?id=2610794788","media":"智通财经","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2610794788?lang=zh_tw&edition=fundamental","pubTime":"2026-02-12 18:57","pubTimestamp":1770893858,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，诺和诺德计划加大在爱尔兰的投资，在当地生产其畅销减肥药Wegovy的口服版本，以供应美国以外的市场。诺和诺德首席执行官迈克·杜斯达尔表示，诺和诺德将扩建其位于爱尔兰中部阿斯隆的生产设施。杜斯达尔称，Wegovy口服药于1月初上市，成为有史以来最成功的药品首发之一，目前已有超过24万名美国患者服用。爱尔兰是全球制药制造中心之一。礼来在当地生产其重磅减肥和糖尿病药物的活性成分。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1404784.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"剑指全球市场！诺和诺德(NVO.US)扩建爱尔兰工厂 欲借口服版Wegovy抢占市场份额","news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["LU1093756168.USD","BK4599","LU1093756325.SGD","NVO","BK4588","BK4585","NVOH","IE00BZ1G4Q59.USD","BK4532","IE00BKVL7J92.USD","LU0154236417.USD","NVOX","BK4007"],"gpt_icon":0},{"id":"2610197339","title":"貝倫貝格：將諾和諾德目標價下調至360丹麥克朗","url":"https://stock-news.laohu8.com/highlight/detail?id=2610197339","media":"中金财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2610197339?lang=zh_tw&edition=fundamental","pubTime":"2026-02-12 14:27","pubTimestamp":1770877621,"startTime":"0","endTime":"0","summary":"贝伦贝格将诺和诺德目标价从415丹麦克朗下调至360丹麦克朗。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://sc.stock.cnfol.com/gushizhibo/20260212/32014623.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"zhongjincaijing_highlight","symbols":["LU1093756168.USD","LU1093756325.SGD","BK4599","LU0154236417.USD","NVOH","NVOX","IE00BZ1G4Q59.USD","BK4585","IE00BKVL7J92.USD","BK4588","BK4532","NVO","BK4007"],"gpt_icon":0},{"id":"2610150992","title":"2026年，這22款藥物值得關注","url":"https://stock-news.laohu8.com/highlight/detail?id=2610150992","media":"药智网","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2610150992?lang=zh_tw&edition=fundamental","pubTime":"2026-02-12 11:27","pubTimestamp":1770866876,"startTime":"0","endTime":"0","summary":"目前，礼来已正式提交该药物的上市申请，有望在2026年实现获批。该药物的III期REDEFINE 4研究结果预计于2026年上半年揭晓。FDA预计将于2026年完成该药物的审评工作。2026年第一季度，预计辉瑞将公布MET-0971的IIb期临床试验数据。02肿瘤领域根据FirstWord Pharma，2026年，肿瘤领域有7款关键药物值得关注。吉利德计划于2026年在","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260212113614a6f1834d&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260212113614a6f1834d&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4599","NVOH","LU1093756168.USD","IE00BZ1G4Q59.USD","NVO","NVOX","BK4532","IE00BKVL7J92.USD","BK4007","LU1093756325.SGD","BK4585","BK4588","LU0154236417.USD"],"gpt_icon":0},{"id":"2610935665","title":"德銀：諾和諾德仍有機會重新把握肥胖症市場的機遇","url":"https://stock-news.laohu8.com/highlight/detail?id=2610935665","media":"环球市场播报","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2610935665?lang=zh_tw&edition=fundamental","pubTime":"2026-02-11 18:28","pubTimestamp":1770805680,"startTime":"0","endTime":"0","summary":"德意志银行分析师Emmanuel Papadakis写道，诺和诺德在适当的时候仍有机会重新把握其在肥胖症市场的机遇。该行仍对诺和诺德持乐观看法，该股市盈率已回落至十几倍的水平。　　该公司Wegovy口服药的上市表现稳健，下半年有潜在的销量利好因素，而且或许最重要的是，关键的cagrisema数据仍有待公布。　　该行将该股目标价从475丹麦克朗下调至400丹麦克朗，并维持买入评级。该股下跌2.4%，至307.55丹麦克朗。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/usstock/c/2026-02-11/doc-inhmmvza3702737.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK4532","IE00BZ1G4Q59.USD","NVO","LU0154236417.USD","IE00BKVL7J92.USD","LU1093756168.USD","BK4585","BK4599","NVOX","BK4588","LU1093756325.SGD","BK4007","NVOH"],"gpt_icon":0},{"id":"2610677932","title":"2026開年大戲：這11個III期臨牀數據，誰會引爆？誰會啞火？","url":"https://stock-news.laohu8.com/highlight/detail?id=2610677932","media":"BiG生物创新社","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2610677932?lang=zh_tw&edition=fundamental","pubTime":"2026-02-11 17:45","pubTimestamp":1770803139,"startTime":"0","endTime":"0","summary":"作者｜YY2026年第一季度将集中披露多项处于3期的关键临床读数，这些结果直接关系核心资产的推进路径，也已被市场纳入当前估值体系之中。该信息公布当日，Alumis股价 上涨约155%至21美元，公司市值增加约13亿美元，创历史新高。关键临床读数COMP006是一项国际多中心、随机、双盲、平行分组的注册性III期研究，9周顶线数据预计将于2026年第一季度披露，评估抑郁症状改善的持续性。最新的官方预期是在2026年2月公布24周的主要终点顶线数据。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260211191533a6eec760&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260211191533a6eec760&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LU0154236417.USD","LU1093756325.SGD","NVO","BK4588","IE00BKVL7J92.USD","BK4532","BK4585","NVOX","LU1093756168.USD","IE00BZ1G4Q59.USD","NVS","BK4007","NVOH","MRK","BK4599","BK4134"],"gpt_icon":0},{"id":"2610098986","title":"德銀：將諾和諾德目標價下調至400丹麥克朗","url":"https://stock-news.laohu8.com/highlight/detail?id=2610098986","media":"格隆汇","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2610098986?lang=zh_tw&edition=fundamental","pubTime":"2026-02-11 15:30","pubTimestamp":1770795023,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.gelonghui.com/rss/live/live.xml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_gelonghui","symbols":["BK4532","BK4585","NVOX","IE00BZ1G4Q59.USD","NVOH","BK4588","NVO","LU1093756325.SGD","IE00BKVL7J92.USD","BK4599","BK4007","LU0154236417.USD","LU1093756168.USD"],"gpt_icon":0},{"id":"2610198552","title":"減肥藥戰局生變：「雙寡頭」分出高下，全球價格血戰中的國產謀突圍丨行業風向標","url":"https://stock-news.laohu8.com/highlight/detail?id=2610198552","media":"钛媒体APP","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2610198552?lang=zh_tw&edition=fundamental","pubTime":"2026-02-11 14:01","pubTimestamp":1770789670,"startTime":"0","endTime":"0","summary":"2月9日，诺和诺德宣布对远程医疗公司Hims提起专利侵权诉讼。礼来也公开支持FDA行动，谴责非法仿制药对患者健康的危害。在专利战爆发的同时，FDA对诺和诺德的双面监管则更具深意。FDA要求诺和诺德15个工作日内提交整改方案，否则将限制产品推广。中国市场成必争之地随着GLP-1减肥药的竞争进入深水区，价格战已从欧美市场蔓延至全球，而中国市场成为巨头角力的关键阵地，国产药企则在仿制药与创新药两条赛道上加速突围。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260211141535a6ed962b&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260211141535a6ed962b&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4532","LLY","LU0154236417.USD","NVO","NVOH","LU1093756325.SGD","IE00BKVL7J92.USD","LU1093756168.USD","NVOX","IE00BZ1G4Q59.USD","BK4599","BK4588","BK4585","BK4007"],"gpt_icon":0},{"id":"2610625648","title":"巔峯之戰！2026藥王爭霸：禮來封神，艾伯維、賽諾菲血拼，強生跌下神壇","url":"https://stock-news.laohu8.com/highlight/detail?id=2610625648","media":"E药经理人","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2610625648?lang=zh_tw&edition=fundamental","pubTime":"2026-02-10 21:18","pubTimestamp":1770729506,"startTime":"0","endTime":"0","summary":"2026年畅销药战场，风云诡谲，格局重塑。回望战场，自2023年底减重适应证获批以来，礼来替尔泊肽仅用两年时间，便以翻倍之势，硬生生从诺和诺德手中夺走“药王”桂冠。强生乌司奴单抗在2025年销售额骤降41%，仅余60.78亿美元。2026年的全球自免药王或将在艾伯维和赛诺菲之中产生。前者手握利生奇珠单抗，2026年狂揽175.62亿美元，增速接近50%，锋芒毕露。此外，艾伯维还在探索体内CAR-T疗法，用于自免疾病治疗。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260210212833a493d0bc&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260210212833a493d0bc&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["IE0005OL40V9.USD","IE00BDGV0183.EUR","LU2361045086.USD","LU2211815571.USD","SG9999001176.SGD","LU1221951129.SGD","LU1732800096.USD","LU0122379950.USD","LU2357305700.SGD","LU2361044865.SGD","LLY","LU1804176565.USD","LU1066051225.USD","BK4532","LU2491050071.SGD","LU0820562030.AUD","LU0471298777.SGD","ELIL","IE000M9KFDE8.USD","LU1061106388.HKD","LU2347655156.SGD","ELIS","LU1057294990.SGD","IE00B7SZLL34.SGD","LU0097036916.USD","IE00BN8TJ469.HKD","LU0225283273.USD","LU1868837300.USD","LU1366192091.USD","IE00B7KXQ091.USD","LU1983299246.USD","LU0154236417.USD","BK4533","LU0943347566.SGD","IE0009355771.USD","IE00B42XCP33.USD","BK4592","SGXZ57979304.SGD","LU2213496289.HKD","LU2111349929.HKD","SG9999014914.USD","LU0198837287.USD","SG9999002224.SGD","SG9999015986.USD","LU1712237335.SGD","BK4568","SG9999013999.USD","SG9999018857.SGD","LU0238689110.USD","LU1196500208.SGD","BK4599","LU0820561818.USD","LU2361044949.HKD","LU0345770993.USD","SG9999015952.SGD","LU0203345920.USD","LU1244550494.USD","LU0385154629.USD","LU1032955483.USD","SNY","LU1291159041.SGD","LU2271345857.HKD","LU0456855351.SGD","LU0792757196.USD","LU1069344957.HKD","LU2602419157.SGD","SG9999014906.USD","LU0345770308.USD","LU1064131342.USD","LU1551013425.SGD","LU0345769631.USD","LU1720051108.HKD","LU2087625088.SGD","LU1261432733.SGD","IE00BFTCPJ56.SGD","LU1145028129.USD","LU0417517546.SGD","LU0689472784.USD","NVOH","LU2237443978.SGD","LU1244550221.USD","LU1162221912.USD","IE00BLSP4239.USD","LLYX","LU1059921491.USD","LU0109394709.USD","LU2168564149.EUR","LU2491049909.HKD","LU0823416689.USD","IE00BK4W5M84.HKD","IE00BVYPNV92.GBP","LU0320765646.SGD","IE0002141913.USD","LU1127390331.HKD","BK4007","LU0256863902.USD","SG9999001176.USD","IE00B3T34201.USD","LU2592432038.USD","LU1623119135.USD","LU0964807845.USD","LU0289739699.SGD","LU1629891620.HKD","LU2168564222.USD","LU1585245621.USD","LU1221951046.USD","IE0034235303.USD","LU0266013472.USD","IE0002270589.USD","LU2430703251.USD","BK4550","LU2129689431.USD","BK4581","LU1894683348.USD","IE00B2B36J28.USD","LU0889565916.HKD","LU0006306889.USD","NVO","LU0316494557.USD","LU0353189680.USD","LU2237443895.HKD","IE00B1XK9C88.USD","LU1674673691.USD","LU0820561909.HKD","SGXZ99366536.SGD","LU0320765059.SGD","SG9999018865.SGD","BK4588","BK4504","LU2746668461.USD","LU0683600562.USD","LU0354030438.USD","LU0109391861.USD","LU0882574139.USD","LU1280957306.USD","LU2430703178.SGD","SGXZ31699556.SGD","SG9999014898.SGD","LU2505996681.GBP","LU2168563687.JPY","SGXZ81514606.USD","SGXZ51526630.SGD","LU1496350502.SGD","LU0786609619.USD","IE00B19Z3B42.SGD","LU0158827948.USD","IE00BJJMRX11.SGD","LU0345769128.USD","LU0058720904.USD","LU2089284900.SGD","LU1868836591.USD","NVOX","IE00BFXG1179.USD","LLYZ","LU2750360641.GBP","LU0985320562.USD","LU2462157665.USD","LU0203201768.USD","LU1267930730.SGD","LU1868836757.USD","LU0158827781.USD","LU2505996509.AUD","SG9999001440.SGD","IE00B1BXHZ80.USD","LU2112291526.USD","LU0787776722.HKD","LU1093756168.USD","IE00BKPKM429.USD","LU0432979614.USD","IE00BK4W5L77.USD","LU2552382058.USD","IE00BKVL7J92.USD","IE00BKDWB100.SGD","LU0210536198.USD","LU1868837136.USD","LU1868836914.USD","LU0061475181.USD","IE00B3PB1722.GBP","LU1267930813.SGD","LU2168564495.EUR","LU1093756325.SGD","IE00BWXC8680.SGD","LU0098860793.USD","LU2746668974.SGD","IE00BBT3K403.USD","LU2028103732.USD","LU1506573853.SGD","LU0823434583.USD","LU0106261372.USD","LU2129689514.USD","IE00BN29S564.USD","LU0124676726.USD","LU2265009873.SGD","LU2461242641.AUD","IE00BJJMRZ35.SGD","LU2108987350.USD","IE00BJLML261.HKD","IE0004445015.USD","LU2237443382.USD","LU2750360997.AUD","LU1244550577.SGD","SG9999017495.SGD","IE00B775H168.HKD","LU1074936037.SGD","LU1914381329.SGD","LU0823434740.USD","LU2471134879.HKD","LU2237443549.SGD","LU0323591593.USD","IE00BFSS8Q28.SGD","LU1989771016.USD","LU1232071149.USD","IE00BLSP4452.SGD","LU2324357040.USD","BK4559","LU0795875169.SGD","LU1035775433.USD","LU2237443465.HKD","ABBV","IE00BJJMRY28.SGD","LU0203347892.USD","LU0672654240.SGD","LU0708995401.HKD","LU2491050154.USD","LU0354030511.USD","LU2023250504.SGD","LU2456880835.USD","LU1066051811.HKD","LU2417539215.USD","IE00BVYPNW00.USD","LU2168564065.EUR","LU1551013342.USD","LU1974910355.USD","LU0096364046.USD","IE00B4JS1V06.HKD","LU1718418525.SGD","LU2756315318.SGD","LU0114720955.EUR","LU0256863811.USD","LU2237443622.USD","LU1430594728.SGD","LU1548497426.USD","LU2552382132.HKD","LU0912757837.SGD","LU2471134523.USD","LU0471298694.HKD","BK4516","LU1674673428.USD","LU2089283258.USD","BK4534","LU0079474960.USD","LU1917777945.USD","LU0320765992.SGD","LU1032466523.USD","LU2237438978.USD","LU0234572021.USD","IE00BJT1NW94.SGD","LU0882574055.USD","LU1023059063.AUD","SG9999015945.SGD","LU2471134796.USD","LU2430703095.HKD","GB00BDT5M118.USD","LU2129689605.HKD","LU1778281490.HKD","LU2552382215.SGD","IE0004445239.USD","LU0094547139.USD","LU2063271972.USD","LU1935042991.SGD","LU0203202063.USD","SG9999014880.SGD","LU1988902786.USD","LU2133065610.SGD","LU0234570918.USD","IE00B4R5TH58.HKD","LU0466842654.USD","LU2896262040.SGD","LU1929549753.HKD","LU1814569148.SGD","LU2236285917.USD","LU0889566641.SGD","LU1894683264.USD","LU1732799900.SGD","LU2360106947.USD","LU1066051498.USD","LU2471134952.CNY","LU2023251221.USD","LU0353189763.USD","LU0070217475.USD","SG9999002232.USD","IE00BSNM7G36.USD","LU1323610961.USD","IE00BFSS7M15.SGD","IE00BZ1G4Q59.USD","LU2756315664.SGD","IE00BGHQF631.EUR","LU2468319806.SGD","BK4585","LU2023250330.USD","LU2089984988.USD","LU2106854487.HKD","LU0795875086.SGD","LU1720051017.SGD","SG9999015978.USD","LU0689626769.HKD","LU2264538146.SGD","LU1066053197.SGD","IE00B19Z3581.USD","LU0640476718.USD"],"gpt_icon":0},{"id":"2610612515","title":"諾和諾德減重藥廣告被指誤導消費者，FDA發出警告","url":"https://stock-news.laohu8.com/highlight/detail?id=2610612515","media":"第一财经","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2610612515?lang=zh_tw&edition=fundamental","pubTime":"2026-02-10 16:12","pubTimestamp":1770711166,"startTime":"0","endTime":"0","summary":"但诺和诺德称，FDA的最新警告不涉及超级碗广告，而是常规播放的关于司美格鲁肽口服减重药电视广告。去年年底，司美格鲁肽口服减重药获得美国FDA批准，成为全球首个获批上市的GLP-1类口服减重药，早于竞争对手礼来。在FDA的警告信中，监管机构认为，诺和诺德的电视广告误导性地暗示，与其他GLP-1类减重药相比，司美股鲁肽口服减重药效果更佳。FDA要求诺和诺德立即采取行动解决这种违规行为，包括停止所有包含误导性信息的广告。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2026021016173295408f1f&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2026021016173295408f1f&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LU1093756325.SGD","LU0154236417.USD","BK4588","NVO","IE00BZ1G4Q59.USD","NVOH","NVOX","BK4585","BK4599","BK4007","IE00BKVL7J92.USD","LU1093756168.USD","BK4532"],"gpt_icon":0},{"id":"2610961801","title":"藥王易主、山寨藥攪局、專利懸崖倒計時、被指虛假宣傳，諾和諾德全球防線告急","url":"https://stock-news.laohu8.com/highlight/detail?id=2610961801","media":"华夏时报网","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2610961801?lang=zh_tw&edition=fundamental","pubTime":"2026-02-10 14:06","pubTimestamp":1770703564,"startTime":"0","endTime":"0","summary":"作为全球糖尿病与肥胖症治疗领域的绝对巨头，诺和诺德曾凭借司美格鲁肽系列产品缔造医药行业的增长神话，市值一度登顶欧洲上市公司榜首。然而进入2026年，这家丹麦制药巨头却遭遇开年暴击：明星产品司美格鲁肽仅以4亿美元之差痛失“全球药王”宝座，美国市场突现低价“山寨”司美格鲁肽搅局，口服减肥药被FDA指为虚假宣传，叠加专利悬崖倒计时的大背景，诺和诺德全球防线告急。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202602103646576715.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202602103646576715.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["LU0154236417.USD","NVO","BK4532","BK4599","NVOH","BK4585","LU1093756325.SGD","BK4588","IE00BKVL7J92.USD","IE00BZ1G4Q59.USD","NVOX","LLY","BK4007","LU1093756168.USD"],"gpt_icon":0},{"id":"2610416699","title":"藥王易主！馬斯克帶貨的減肥「神藥」賣不動了？","url":"https://stock-news.laohu8.com/highlight/detail?id=2610416699","media":"Ofweek光电信息网","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2610416699?lang=zh_tw&edition=fundamental","pubTime":"2026-02-10 10:38","pubTimestamp":1770691080,"startTime":"0","endTime":"0","summary":"埃隆·马斯克站台的司美格鲁肽痛失全球“药王”王冠。这也使得后者问鼎2025年新“药王”。反观诺和诺德宣布下调2026年销售额指引。信达生物的玛仕度肽、银诺医药的依苏帕格鲁肽α等国产GLP-1产品均于2025年上市。而司美格鲁肽核心专利将于3月20日到期，无疑又给其在华市场竞争又增添了一份挑战。将GLP-1药物的适应症从传统的降糖、减重向多重功效拓展，已成为参与这场竞争的企业的重要突破口。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260210104341a6e86fad&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260210104341a6e86fad&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LU0820561909.HKD","IE0034235303.USD","LU2360106780.USD","SG9999015978.USD","TSLT","BK4511","LU1435385759.SGD","UFO","LU0689472784.USD","LU1861558580.USD","LU2471134952.CNY","LU0077335932.USD","BK4099","IE00BKVL7J92.USD","IE00B19Z8X17.USD","TSLR","LU0823414478.USD","LU2087621335.USD","BK4534","LU1066051225.USD","LU1551013425.SGD","LU2213496289.HKD","LU1548497426.USD","LU2756315664.SGD","BK4543","TSLG","LU2756315318.SGD","LU0719512351.SGD","LU0820562030.AUD","LU0348723411.USD","LU0154236417.USD","LU2290526834.HKD","TSII","BK4007","07766","LU1066051498.USD","BK4585","LU1366192091.USD","TSYY","LU0345770308.USD","TSLS","IE00B1XK9C88.USD","TSLP","TSLZ","BK4581","LU1720051108.HKD","BK4592","LU2326559502.SGD","BK4599","LU0234572021.USD","LU0345769631.USD","LU0053666078.USD","LU0708995401.HKD","IE00B19Z8W00.USD","LU2462157665.USD","LU1093756325.SGD","LU0097036916.USD","BK4550","LU0109391861.USD","LU0316494557.USD","LU0345769128.USD","IE00BK4W5L77.USD","IE00BK4W5M84.HKD","LU2023250330.USD","LU2471134523.USD","LLY","LU1093756168.USD","TSLO","TSL","LU2750360997.AUD","LU1551013342.USD","TSLW","TESL","LU1066051811.HKD","LU1914381329.SGD","LU0234570918.USD","LU1674673691.USD","LU1861559042.SGD","LU0323591593.USD","LU1861215975.USD","LU1861220033.SGD","LU1145028129.USD","TSLL","LU1066053197.SGD","LU2063271972.USD","LU2471134879.HKD","LU1839511570.USD","LU2360107168.USD","IE00B19Z9505.USD","BK4555","IE00BJLML261.HKD","IE00BSNM7G36.USD","LU1674673428.USD","BK4588","BK4548","IE00B1BXHZ80.USD","TSLY","BK4516","LU1267930730.SGD","LU2456880835.USD","BK4551","LU0672654240.SGD","LU0082616367.USD","BK4574","BK4527","LU1778281490.HKD","SG9999015945.SGD","LU2403377893.USD","LU0823411888.USD","BK4533","LU2420271590.USD","LU1629891620.HKD","IE00BWXC8680.SGD","LU2249611893.SGD","LU2750360641.GBP","LU1852331112.SGD","LU0198837287.USD","LU0345770993.USD","LU2108987350.USD","LU1429558221.USD","LU2471134796.USD","LU0964807845.USD","LU2357305700.SGD","LU0320765059.SGD","SG9999015986.USD","BK4532","LU2896262040.SGD","NVOX","SG9999015952.SGD","LU2417539215.USD","LU0820561818.USD","LU2602419157.SGD","BK4604","BK4612","NVO","IE00BZ1G4Q59.USD","LU0466842654.USD","LU1720051017.SGD","TSLI","LU2250418816.HKD","NVOH","BK4598","LU2236285917.USD","LU0210536198.USD","LU0056508442.USD","CRSH","LU0943347566.SGD","TSDD","LU1232071149.USD","TSLQ"],"gpt_icon":0},{"id":"2610693315","title":"諾和諾德：GLP-1/GIP/GCG啓動減重二期臨牀","url":"https://stock-news.laohu8.com/highlight/detail?id=2610693315","media":"医药笔记","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2610693315?lang=zh_tw&edition=fundamental","pubTime":"2026-02-10 08:25","pubTimestamp":1770683156,"startTime":"0","endTime":"0","summary":"UBT251为联邦制药自主研发的GLP-1/GIP/GCG受体激动剂。2025年3月，联邦制药宣布将GLP-1/GIP/GCG受体激动剂UBT251的大中华区外全球权益授权给诺和诺德，后者支付2亿美元预付款、18亿美元里程碑金额，以及一定比例的销售分成。总结2025年12月，礼来公布GLP-1/GIP/GCG三靶点激动剂Retatrutide首个三期临数据，治疗肥胖合并骨关节炎三期临床TRIUMPH-4的最新数据，9mg、12mg Retatrutide治疗68周减重幅度分别为26.4%、28.7%，安慰剂组减重2.1%。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2026021008564095407eb9&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2026021008564095407eb9&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LU1093756168.USD","BK4144","BK4588","IE00BZ1G4Q59.USD","BK4007","BK4599","LU1093756325.SGD","NVO","NVOH","IE00BKVL7J92.USD","BK4590","BK4532","03933","BK4585","NVOX","LU0154236417.USD"],"gpt_icon":0}],"pageSize":20,"totalPage":4,"pageCount":1,"totalSize":80,"code":"91000000","status":"200"}]}}